AI Summary & Key Takeaways
AI InsightThere was a statistically significant difference inthe median survival rates between the groups (p<0.001).CONCLUSION: Patients with solitary metastasis or single metastases tolerated whole brain radiotherapy with a conventional boost.Although the overall survival rates were numerically better in the high dose RT group, the difference was not statistically significant.Prospective studies with a larger sample size are needed to consolidate our results.
📌 3 Key Takeaways
Özet
AIM: To evaluate the clinical characteristics and treatment outcomes of non-small cell lung cancer (NSCLC) patients with brainmetastasis, who were treated by whole brain radiotherapy with a conventional boost at a single institution.MATERIAL and METHODS: A total of 296 patients diagnosed with NSCLC with brain metastasis and referred to our clinic forradiotherapy between 2000 and 2017 were included in this retrospective study.RESULTS: The median age was 60.8 ± 12.1 years, with a range of 21–85 years. The estimated median survival time for all patientswas 7.81 ± 0.66 months (95% CI: 6.52–9.11). The one-year survival, two-year survival and three-year survival rates were 18.8%,5.8% and 2.9%, respectively. The median survival of patients with solitary brain metastasis who received 45 Gy radiotherapy was14.70 ± 2.80 months (95% CI: 9.20–20.20). These patients had 6 and 12 months survival rates of 65.4% and 42.6%, respectively.The median survival time of patients with solitary brain metastasis who received > 45 Gy radiotherapywas 13.86 ± 2.56 months(95% CI: 8.08–18.02). These patients had 6 and 12 months survival rates of 66.2% and 27.2%, respectively. There was no significantdifference between the two groups (p=0.321). The median survival duration of patients under 65 years was 9.65 ± 1.02 months. Themedian survival time of patients aged 65 years and overwas 5.15 ± 0.51 months. There was a statistically significant difference inthe median survival rates between the groups (p<0.001).CONCLUSION: Patients with solitary metastasis or single metastases tolerated whole brain radiotherapy with a conventional boost.Although the overall survival rates were numerically better in the high dose RT group, the difference was not statistically significant.Prospective studies with a larger sample size are needed to consolidate our results.